Phenergan (Promethazine) in Dialysis Patients
Primary Recommendation
Promethazine can be safely used in dialysis patients at standard adult doses without dose adjustment, as it is primarily metabolized by the liver rather than excreted renally. 1
Standard Dosing for Dialysis Patients
The FDA-approved dosing for promethazine applies to dialysis patients without modification:
- Nausea and vomiting: 12.5 to 25 mg IV/IM, not more frequently than every 4 hours 1
- Allergic conditions: 25 mg IV/IM, may repeat within 2 hours if necessary 1
- Sedation: 25 to 50 mg IV/IM for nighttime sedation in hospitalized patients 1
No dose reduction is required for renal failure or hemodialysis patients because promethazine undergoes hepatic metabolism with a plasma half-life of 9-16 hours, and renal impairment does not significantly alter its pharmacokinetics. 2
Administration Guidelines
Route Selection
- Deep intramuscular injection is the preferred route to minimize risk of severe tissue injury including gangrene. 1
Intravenous Administration (When Necessary)
If IV administration is required in dialysis patients:
- Dilute the dose in 50 mL of 0.9% sodium chloride (e.g., 12.5 mg diluted to maximum concentration of 1 mg/mL; 25 mg to 50 mL) 1
- Infuse slowly over 20-40 minutes at maximum rate of 2.5 mL/minute 1
- Use a large vein, preferably via central venous catheter—do NOT use hand or wrist veins 1
- Immediately discontinue if pain occurs at injection site and evaluate for arterial injection or perivascular extravasation 1, 3
Critical Safety Considerations in Dialysis Patients
Hypotension Risk
- Dialysis patients are at increased risk of hypotension due to volume shifts during dialysis and concurrent antihypertensive medications. 2
- Infuse promethazine slowly (≤25 mg/min) to minimize hypotension risk. 2
- Avoid administration immediately before or during dialysis sessions when patients are most volume-depleted and hemodynamically unstable.
Central Nervous System Toxicity
- A characteristic acute psychosis has been reported in dialysis patients receiving phenothiazines (including promethazine), manifesting as extreme restlessness, auditory/visual hallucinations, and belligerent behavior. 4
- This toxicity developed within 2-7 days of phenothiazine initiation and resolved slowly after drug cessation; hemodialysis did not accelerate recovery. 4
- Use the lowest effective dose and monitor closely for neuropsychiatric symptoms, particularly in the first week of therapy.
Respiratory Depression
- Promethazine causes respiratory depression, which may be potentiated by concurrent opioids or benzodiazepines commonly used in dialysis patients. 2, 1
- Reduce doses of concomitant sedatives and analgesics when using promethazine. 1
Extrapyramidal Effects
- Adverse effects range from restlessness to oculogyric crises, and include neuroleptic malignant syndrome. 2
Practical Dosing Strategy
Low-Dose Approach
Consider starting with 6.25 to 12.5 mg IV for nausea/vomiting in dialysis patients, as this provides equivalent antiemetic efficacy to standard 25 mg doses while reducing sedation risk. 5
- 6.25 mg IV promethazine relieved nausea/vomiting in 74% of patients at 1 hour and 67% at 3 hours, with minimal sedation (median sedation score = 3-4 on scale where 4 = fully awake). 5
- 12.5 mg IV achieved 68% relief at 1 hour and 80% at 3 hours. 5
- Doses above 12.5 mg do not improve anxiety relief, sedation quality, or patient acceptance. 6
Timing Relative to Dialysis
- Administer promethazine after hemodialysis sessions rather than before or during, to avoid compounding hypotension from ultrafiltration.
- Promethazine is not significantly removed by hemodialysis due to high protein binding and hepatic metabolism, so post-dialysis supplementation is unnecessary. 7
Drug Interactions in Dialysis Patients
- Reduce doses of opioid analgesics and benzodiazepines by 25-50% when co-administering with promethazine to prevent excessive CNS and respiratory depression. 1
- Monitor for additive hypotensive effects with antihypertensive medications commonly used in dialysis patients (ACE inhibitors, beta-blockers, calcium channel blockers). 8
Monitoring Parameters
- Blood pressure before and after administration, especially in volume-depleted patients
- Level of consciousness and respiratory rate every 15-30 minutes during and after IV infusion
- Neuropsychiatric symptoms (agitation, hallucinations, confusion) particularly in the first week of therapy 4
- Injection site assessment for pain, swelling, or discoloration indicating extravasation 3
Common Pitfalls to Avoid
- Do not assume dose adjustment is needed—promethazine does not require renal dose reduction despite severe kidney disease. 1, 7
- Do not administer undiluted IV push—this significantly increases risk of tissue necrosis and gangrene. 1, 3
- Do not use peripheral hand/wrist veins for IV administration—arterial injection or extravasation in these sites causes devastating limb-threatening injury. 1, 3
- Do not continue standard doses of opioids/benzodiazepines—promethazine potentiates their effects and requires dose reduction of concurrent CNS depressants. 1
- Do not dismiss early neuropsychiatric symptoms—phenothiazine-induced psychosis in dialysis patients can progress rapidly and requires immediate drug discontinuation. 4